SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $167,410,003 | -7.8% | 6,072,180 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $181,666,679 | -14.7% | 6,043,469 | +2.8% | 0.00% | -20.0% |
| Q1 2023 | $213,070,985 | +3.2% | 5,881,065 | +1.6% | 0.01% | -16.7% |
| Q4 2022 | $206,527,874 | +7.4% | 5,789,960 | +1.9% | 0.01% | 0.0% |
| Q3 2022 | $192,276,000 | +18.3% | 5,680,242 | +1.1% | 0.01% | +20.0% |
| Q2 2022 | $162,544,000 | -9.2% | 5,620,448 | +1.5% | 0.01% | +25.0% |
| Q1 2022 | $179,015,000 | +11.4% | 5,538,820 | +0.5% | 0.00% | 0.0% |
| Q4 2021 | $160,764,000 | +10.0% | 5,513,149 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $146,091,000 | -13.5% | 5,477,743 | -0.1% | 0.00% | 0.0% |
| Q2 2021 | $168,865,000 | +18.3% | 5,484,424 | +0.5% | 0.00% | 0.0% |
| Q1 2021 | $142,801,000 | +7.1% | 5,454,555 | +3.0% | 0.00% | 0.0% |
| Q4 2020 | $133,300,000 | +22.8% | 5,298,078 | +1.7% | 0.00% | 0.0% |
| Q3 2020 | $108,571,000 | -15.7% | 5,209,740 | -3.9% | 0.00% | -20.0% |
| Q2 2020 | $128,773,000 | +31.0% | 5,422,018 | -0.8% | 0.01% | +25.0% |
| Q1 2020 | $98,288,000 | -21.9% | 5,463,479 | +3.0% | 0.00% | 0.0% |
| Q4 2019 | $125,856,000 | -14.9% | 5,305,889 | -1.4% | 0.00% | -20.0% |
| Q3 2019 | $147,917,000 | -16.4% | 5,382,715 | +0.7% | 0.01% | -28.6% |
| Q2 2019 | $176,873,000 | -4.7% | 5,345,217 | +0.9% | 0.01% | 0.0% |
| Q1 2019 | $185,556,000 | +6.6% | 5,295,541 | +1.1% | 0.01% | -12.5% |
| Q4 2018 | $174,009,000 | -32.5% | 5,238,062 | +2.4% | 0.01% | -20.0% |
| Q3 2018 | $257,614,000 | -13.1% | 5,116,478 | +3.2% | 0.01% | -16.7% |
| Q2 2018 | $296,599,000 | +35.3% | 4,955,713 | +3.6% | 0.01% | +20.0% |
| Q1 2018 | $219,157,000 | +20.0% | 4,785,082 | +4.4% | 0.01% | +25.0% |
| Q4 2017 | $182,597,000 | +1.7% | 4,582,096 | +2.1% | 0.01% | 0.0% |
| Q3 2017 | $179,563,000 | +19.0% | 4,489,064 | +28.2% | 0.01% | +14.3% |
| Q2 2017 | $150,873,000 | +91.6% | 3,500,535 | +39.1% | 0.01% | +75.0% |
| Q1 2017 | $78,762,000 | +32.2% | 2,516,335 | +6.6% | 0.00% | +33.3% |
| Q4 2016 | $59,596,000 | +9.4% | 2,360,241 | +7.2% | 0.00% | 0.0% |
| Q3 2016 | $54,468,000 | +36.7% | 2,202,543 | +12.6% | 0.00% | +50.0% |
| Q2 2016 | $39,854,000 | +46.9% | 1,956,476 | +10.0% | 0.00% | 0.0% |
| Q1 2016 | $27,127,000 | +17.3% | 1,778,828 | +3.4% | 0.00% | 0.0% |
| Q4 2015 | $23,119,000 | +15.5% | 1,720,166 | +20.6% | 0.00% | +100.0% |
| Q3 2015 | $20,017,000 | -9.7% | 1,426,696 | +9.3% | 0.00% | 0.0% |
| Q2 2015 | $22,171,000 | +107.1% | 1,305,729 | +47.4% | 0.00% | 0.0% |
| Q1 2015 | $10,708,000 | +57.0% | 885,629 | +7.8% | 0.00% | – |
| Q4 2014 | $6,819,000 | +1.5% | 821,509 | +6.3% | 0.00% | -100.0% |
| Q3 2014 | $6,717,000 | -6.7% | 772,920 | +17.5% | 0.00% | 0.0% |
| Q2 2014 | $7,203,000 | +52.4% | 657,835 | +24.5% | 0.00% | – |
| Q1 2014 | $4,725,000 | +54.8% | 528,561 | +30.6% | 0.00% | – |
| Q4 2013 | $3,052,000 | +16.9% | 404,657 | +13.6% | 0.00% | – |
| Q3 2013 | $2,611,000 | +15.1% | 356,192 | +0.9% | 0.00% | – |
| Q2 2013 | $2,269,000 | – | 352,883 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |